AIM: To investigate the effects of arbidol hydrochloride (ARB), a widely used antiviral agent, on the inflammation induced by influenza virus. METHODS: MDCK cells were infected with seasonal influenza A/FM/1/47 (H1N1) or pandemic influenza A/Hubei/71/2009 (H1N1). In vitro cytotoxicity and antiviral activity of ARB was determined using MTT assay. BALB/c mice were infected with A/FM/1/47 (H1N1). Four hours later the mice were administered ARB (45, 90, and 180 mg·kg(-1)·d(-1)) or the neuraminidase inhibitor oseltamivir (22.5 mg·kg(-1)·d(-1)) via oral gavage once a day for 5 d. Body-weight, median survival time, viral titer, and lung index of the mice were measured. The levels of inflammatory cytokines were examined using real-time RT-PCR and ELISA. RESULTS: Both H1N1 stains were equally sensitive to ARB as tested in vitro. In the infected mice, ARB (90 and 180 mg·kg(-1)·d(-1)) significantly decreased the mortality, alleviated virus-induced lung lesions and viral titers. Furthermore, ARB suppressed the levels of IL-1β, IL-6, IL-12, and TNF-α, and elevated the level of IL-10 in the bronchoalveolar lavage fluids and lung tissues. However, ARB did not significantly affect the levels of IFN-α and IFN-γ, but reduced the level of IFN-β1 in lung tissues at 5 dpi. In peritoneal macrophages challenged with A/FM/1/47 (H1N1) or poly I:C, ARB (20 μmol/L) suppressed the levels of IL-1β, IL-6, IL-12, and TNF-α, and elevated the level of IL-10. Oseltamivir produced comparable alleviation of virus-induced lung lesions with more reduction in the viral titers, but less effective modulation of the inflammatory cytokines. CONCLUSION: ARB efficiently inhibits both H1N1 stains and diminishes both viral replication and acute inflammation through modulating the expression of inflammatory cytokines.
AIM: To investigate the effects of arbidol hydrochloride (ARB), a widely used antiviral agent, on the inflammation induced by influenza virus. METHODS: MDCK cells were infected with seasonal influenza A/FM/1/47 (H1N1) or pandemic influenza A/Hubei/71/2009 (H1N1). In vitro cytotoxicity and antiviral activity of ARB was determined using MTT assay. BALB/c mice were infected with A/FM/1/47 (H1N1). Four hours later the mice were administered ARB (45, 90, and 180 mg·kg(-1)·d(-1)) or the neuraminidase inhibitor oseltamivir (22.5 mg·kg(-1)·d(-1)) via oral gavage once a day for 5 d. Body-weight, median survival time, viral titer, and lung index of the mice were measured. The levels of inflammatory cytokines were examined using real-time RT-PCR and ELISA. RESULTS: Both H1N1 stains were equally sensitive to ARB as tested in vitro. In the infected mice, ARB (90 and 180 mg·kg(-1)·d(-1)) significantly decreased the mortality, alleviated virus-induced lung lesions and viral titers. Furthermore, ARB suppressed the levels of IL-1β, IL-6, IL-12, and TNF-α, and elevated the level of IL-10 in the bronchoalveolar lavage fluids and lung tissues. However, ARB did not significantly affect the levels of IFN-α and IFN-γ, but reduced the level of IFN-β1 in lung tissues at 5 dpi. In peritoneal macrophages challenged with A/FM/1/47 (H1N1) or poly I:C, ARB (20 μmol/L) suppressed the levels of IL-1β, IL-6, IL-12, and TNF-α, and elevated the level of IL-10. Oseltamivir produced comparable alleviation of virus-induced lung lesions with more reduction in the viral titers, but less effective modulation of the inflammatory cytokines. CONCLUSION:ARB efficiently inhibits both H1N1 stains and diminishes both viral replication and acute inflammation through modulating the expression of inflammatory cytokines.
Authors: I Julkunen; T Sareneva; J Pirhonen; T Ronni; K Melén; S Matikainen Journal: Cytokine Growth Factor Rev Date: 2001 Jun-Sep Impact factor: 7.638
Authors: Dmytro S Silin; Oksana V Lyubomska; Feliks I Ershov; Valeriy M Frolov; Galyna A Kutsyna Journal: Curr Pharm Des Date: 2009 Impact factor: 3.116
Authors: Terrence M Tumpey; Christopher F Basler; Patricia V Aguilar; Hui Zeng; Alicia Solórzano; David E Swayne; Nancy J Cox; Jacqueline M Katz; Jeffery K Taubenberger; Peter Palese; Adolfo García-Sastre Journal: Science Date: 2005-10-07 Impact factor: 47.728
Authors: I A Leneva; I T Fediakina; M Iu Eropkin; N V Gudova; A A Romanovskaia; D M Danilenko; S M Vinogradova; A Iu Lepeshkin; A M Shestopalov Journal: Vopr Virusol Date: 2010 May-Jun
Authors: Megan J Brooks; Elena I Burtseva; Philip J Ellery; Glenn A Marsh; Andrew M Lew; Anatoly N Slepushkin; Suzanne M Crowe; Gregory A Tannock Journal: J Med Virol Date: 2011-10-25 Impact factor: 2.327
Authors: Susan L Fink; Lucia Vojtech; Jessica Wagoner; Natalie S J Slivinski; Konner J Jackson; Ruofan Wang; Sudip Khadka; Priya Luthra; Christopher F Basler; Stephen J Polyak Journal: Sci Rep Date: 2018-06-12 Impact factor: 4.379
Authors: Jan Haviernik; Michal Štefánik; Martina Fojtíková; Sabrina Kali; Noël Tordo; Ivo Rudolf; Zdeněk Hubálek; Luděk Eyer; Daniel Ruzek Journal: Viruses Date: 2018-04-10 Impact factor: 5.048
Authors: Sonu Bhaskar; Akansha Sinha; Maciej Banach; Shikha Mittoo; Robert Weissert; Joseph S Kass; Santhosh Rajagopal; Anupama R Pai; Shelby Kutty Journal: Front Immunol Date: 2020-07-10 Impact factor: 7.561